董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Peter Beetham Interim Chief Executive Officer, President and Chief Operating Officer and Director 63 87.05万美元 未持股 2025-11-05
Rory Riggs Director and Chairman of the Board 72 12.55万美元 未持股 2025-11-05
Gerhard Prante Director 83 7.29万美元 未持股 2025-11-05
Mark Finn Lead Independent Director 82 6.25万美元 未持股 2025-11-05
Keith Walker Director 77 6.00万美元 未持股 2025-11-05
August Moretti Director 75 未披露 未持股 2025-11-05
Jean Pierre Lehmann Director 56 未披露 未持股 2025-11-05
Craig Wichner Director 56 未披露 未持股 2025-11-05
Kimberly A. Box Director 65 未披露 未持股 2025-11-05

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Peter Beetham Interim Chief Executive Officer, President and Chief Operating Officer and Director 63 87.05万美元 未持股 2025-11-05
Greg Gocal Chief Scientific Officer and Executive Vice President 56 71.39万美元 未持股 2025-11-05
Cornelis Broos Chief Financial Officer 54 未披露 未持股 2025-11-05
Noel Sauer Senior Vice President, Research 58 未披露 未持股 2025-11-05
Jason Stokes Chief Legal Officer, General Counsel and Corporate Secretary 54 未披露 未持股 2025-11-05

董事简历

中英对照 |  中文 |  英文
Peter Beetham

Peter Beetham是Cibus Global的联合创始人,担任Cibus Ltd.的首席执行官兼总裁,并自2014年7月起担任Cibus Global的首席执行官兼总裁。Beetham先生还任职于Cibus Ltd.的董事会。此前,Beetham博士是Cibus Global研究与开发的高级副总裁,并担任其他行政职务。Beetham博士拥有超过30年的农业经验。加入Cibus公司之前,他曾担任Valigen公司的工厂和工业产品部门的研究董事,以及Kimeragen公司的高级科学家,在那里他曾领导研究团队探索基因靶向。他丰富的研究经验的一部分是在康奈尔大学(Cornell University)的博伊斯·汤普森研究所(Boyce Thompson Institute),在那里他是博士后科学家和导致Cibus RTDS技术的早期工作的先驱之一。Beetham博士从1985年到1992年受雇于澳大利亚维多利亚州农业和农村事务部。他曾担任植物研究所(the Plant Research Institute)的科学官员,与东南亚和南太平洋的研究团体合作。Beetham博士在澳大利亚布里斯班QUT获得植物分子病毒学博士学位,是理学学士学位。莫纳什大学荣誉毕业生,墨尔本,澳大利亚。


Peter Beetham is a co-founder of Cibus Global and serves as Cibus Ltd.’s Chief Executive Officer & President and has served as the Chief Executive Officer & President of Cibus Global since July 2014. Mr. Beetham also serves on the Board of Directors of Cibus Ltd. Previously, Dr. Beetham was Senior Vice President of Research and Development at Cibus Global and served in other executive capacities. Dr. Beetham has over 30 years of experience in agriculture. Prior to joining Cibus, Dr. Beetham was Research Director of the Plant and Industrial Products Division at ValiGen and a Senior Scientist at Kimeragen where he led research teams exploring gene targeting. Part of his extensive research experience was at the Boyce Thompson Institute at Cornell University, where he was a postdoctoral scientist and one of the pioneers of the early work that led to the Cibus RTDS technologies. Dr. Beetham was employed by the Department of Agriculture and Rural Affairs, Victoria, Australia from 1985 to 1992. He served as a scientific officer based at the Plant Research Institute, working with research groups throughout Southeast Asia and the South Pacific. Dr. Beetham received his Ph.D. in Plant Molecular Virology from QUT in Brisbane, Australia and is a B.Sc. Hons graduate of Monash University, Melbourne, Australia.
Peter Beetham是Cibus Global的联合创始人,担任Cibus Ltd.的首席执行官兼总裁,并自2014年7月起担任Cibus Global的首席执行官兼总裁。Beetham先生还任职于Cibus Ltd.的董事会。此前,Beetham博士是Cibus Global研究与开发的高级副总裁,并担任其他行政职务。Beetham博士拥有超过30年的农业经验。加入Cibus公司之前,他曾担任Valigen公司的工厂和工业产品部门的研究董事,以及Kimeragen公司的高级科学家,在那里他曾领导研究团队探索基因靶向。他丰富的研究经验的一部分是在康奈尔大学(Cornell University)的博伊斯·汤普森研究所(Boyce Thompson Institute),在那里他是博士后科学家和导致Cibus RTDS技术的早期工作的先驱之一。Beetham博士从1985年到1992年受雇于澳大利亚维多利亚州农业和农村事务部。他曾担任植物研究所(the Plant Research Institute)的科学官员,与东南亚和南太平洋的研究团体合作。Beetham博士在澳大利亚布里斯班QUT获得植物分子病毒学博士学位,是理学学士学位。莫纳什大学荣誉毕业生,墨尔本,澳大利亚。
Peter Beetham is a co-founder of Cibus Global and serves as Cibus Ltd.’s Chief Executive Officer & President and has served as the Chief Executive Officer & President of Cibus Global since July 2014. Mr. Beetham also serves on the Board of Directors of Cibus Ltd. Previously, Dr. Beetham was Senior Vice President of Research and Development at Cibus Global and served in other executive capacities. Dr. Beetham has over 30 years of experience in agriculture. Prior to joining Cibus, Dr. Beetham was Research Director of the Plant and Industrial Products Division at ValiGen and a Senior Scientist at Kimeragen where he led research teams exploring gene targeting. Part of his extensive research experience was at the Boyce Thompson Institute at Cornell University, where he was a postdoctoral scientist and one of the pioneers of the early work that led to the Cibus RTDS technologies. Dr. Beetham was employed by the Department of Agriculture and Rural Affairs, Victoria, Australia from 1985 to 1992. He served as a scientific officer based at the Plant Research Institute, working with research groups throughout Southeast Asia and the South Pacific. Dr. Beetham received his Ph.D. in Plant Molecular Virology from QUT in Brisbane, Australia and is a B.Sc. Hons graduate of Monash University, Melbourne, Australia.
Rory Riggs

Rory Riggs自2020年6月以来一直是我们的董事会成员,并于2000年至2020年6月担任Royalty Pharma投资委员会成员。Riggs先生于1996年联合创立Royalty Pharma Investments,并自2003年起担任其投资委员会主席。Riggs先生于2010年创立Syntax&Locus Analytics,并担任其首席执行官。Riggs从1995年到2000年担任Biomatrix总裁。Riggs先生担任或曾经担任几个董事会成员,包括FibroGen,Cibus,Sugen,细胞内疗法和Biomatrix。Riggs先生拥有Middlebury College的学士学位和Columbia University的工商管理硕士学位。


Rory Riggs has been a member of Royalty Pharma Plc Board since June 2020 and was a member of the Investment Committee of Royalty Pharma from 2000 to June 2020. Mr. Riggs co-founded Royalty Pharma Investments in 1996 and served as the chairman of its investment committee from 2003 to 2020. Since April 2010, Mr. Riggs has served as founder and Chief Executive Officer of Syntax, LLC and Locus Analytics, LLC, sister development-stage ventures focused on creating a new information technology platform for business and finance. Mr. Riggs has a B.A. from Middlebury College and an MBA from Columbia University.
Rory Riggs自2020年6月以来一直是我们的董事会成员,并于2000年至2020年6月担任Royalty Pharma投资委员会成员。Riggs先生于1996年联合创立Royalty Pharma Investments,并自2003年起担任其投资委员会主席。Riggs先生于2010年创立Syntax&Locus Analytics,并担任其首席执行官。Riggs从1995年到2000年担任Biomatrix总裁。Riggs先生担任或曾经担任几个董事会成员,包括FibroGen,Cibus,Sugen,细胞内疗法和Biomatrix。Riggs先生拥有Middlebury College的学士学位和Columbia University的工商管理硕士学位。
Rory Riggs has been a member of Royalty Pharma Plc Board since June 2020 and was a member of the Investment Committee of Royalty Pharma from 2000 to June 2020. Mr. Riggs co-founded Royalty Pharma Investments in 1996 and served as the chairman of its investment committee from 2003 to 2020. Since April 2010, Mr. Riggs has served as founder and Chief Executive Officer of Syntax, LLC and Locus Analytics, LLC, sister development-stage ventures focused on creating a new information technology platform for business and finance. Mr. Riggs has a B.A. from Middlebury College and an MBA from Columbia University.
Gerhard Prante

Gerhard Prante担任Cibus Ltd.的Vice Chairman of the Board,并自2011年起担任Cibus Global的董事会成员,自2018年起担任Vice Chairman of the Board。Prante博士于1985年成为Hoechst AG的农业部门主管。成立Agrevo GmbH公司(Hoechst AG和Schering AG的合资企业)之后,他曾担任其首席执行官兼董事会主席。Hoechst和Rhone Polenc合并到Aventis SE之后,Prante博士担任Aventis CropScience(后来被Bayer AG收购)的副首席执行官。他随后担任行业顾问,并任职于几个董事会,包括Bayer CropScience AG、Gerresheimer AG、Allessa GmbH和Direvo Industrial Biotechnology GmbH。他在德国基尔大学(Kiel University)学习农业,并于1970年完成农业科学博士学位。Prante博士曾在多个行业协会任职,有时担任其主席,包括德国作物保护和化肥协会(IVA)、欧洲作物保护协会(ECPA)、全球作物保护联合会(GCPF)、全球植物科学行业联合会(CropLife International)、德国生物技术行业协会(DIB)和可持续农业联合会。在他的职业生涯中,Prante博士自上世纪80年代中期以来一直是将生物技术整合到农业综合企业的坚定支持者,领导了Agrevo对植物遗传系统7亿美元的收购,并在加拿大建立了Invigor Canola业务,此外还收购和整合了几家种子公司。


Gerhard Prante serves as Vice Chairman of the Board of Directors of Cibus Ltd., and has served on the Board of Directors of Cibus Global since 2011 and as Vice Chairman of the Board since 2018. Dr. Prante became Head of the Agriculture division of Hoechst AG in 1985. After forming AgrEvo GmbH a joint venture of Hoechst AG and Schering AG, he served as its Chief Executive Officer and Chairman of the Board. Following the merger of Hoechst and Rhone Polenc into Aventis SE, Dr. Prante served as Deputy Chief Executive Officer of Aventis CropScience (which was later acquired by Bayer AG). He then worked as an industry consultant, and served on several boards, including Bayer CropScience AG, Gerresheimer AG, Allessa GmbH and Direvo Industrial Biotechnology GmbH. He studied Agriculture at Kiel University in Germany, and finished his Ph.D. in Agricultural Sciences in 1970. Dr. Prante has served on numerous industry associations, at times as their president, including German Crop Protection and Fertilizer Association (IVA), Europe Crop Protection Association (ECPA), Global Crop Protection Federation (GCPF), Global Plant Science Industry Federation (Croplife International), German Association of Biotech Industry (DIB), and the Federation of Sustainable Agriculture. In his career, Dr. Prante has been a strong proponent of the integration of biotechnology into agribusiness since the mid-1980s, led the $0.7 billion acquisition of Plant Genetic Systems by AgrEvo, and built the InVigor canola business in Canada, in addition to buying and integrating several seed companies.
Gerhard Prante担任Cibus Ltd.的Vice Chairman of the Board,并自2011年起担任Cibus Global的董事会成员,自2018年起担任Vice Chairman of the Board。Prante博士于1985年成为Hoechst AG的农业部门主管。成立Agrevo GmbH公司(Hoechst AG和Schering AG的合资企业)之后,他曾担任其首席执行官兼董事会主席。Hoechst和Rhone Polenc合并到Aventis SE之后,Prante博士担任Aventis CropScience(后来被Bayer AG收购)的副首席执行官。他随后担任行业顾问,并任职于几个董事会,包括Bayer CropScience AG、Gerresheimer AG、Allessa GmbH和Direvo Industrial Biotechnology GmbH。他在德国基尔大学(Kiel University)学习农业,并于1970年完成农业科学博士学位。Prante博士曾在多个行业协会任职,有时担任其主席,包括德国作物保护和化肥协会(IVA)、欧洲作物保护协会(ECPA)、全球作物保护联合会(GCPF)、全球植物科学行业联合会(CropLife International)、德国生物技术行业协会(DIB)和可持续农业联合会。在他的职业生涯中,Prante博士自上世纪80年代中期以来一直是将生物技术整合到农业综合企业的坚定支持者,领导了Agrevo对植物遗传系统7亿美元的收购,并在加拿大建立了Invigor Canola业务,此外还收购和整合了几家种子公司。
Gerhard Prante serves as Vice Chairman of the Board of Directors of Cibus Ltd., and has served on the Board of Directors of Cibus Global since 2011 and as Vice Chairman of the Board since 2018. Dr. Prante became Head of the Agriculture division of Hoechst AG in 1985. After forming AgrEvo GmbH a joint venture of Hoechst AG and Schering AG, he served as its Chief Executive Officer and Chairman of the Board. Following the merger of Hoechst and Rhone Polenc into Aventis SE, Dr. Prante served as Deputy Chief Executive Officer of Aventis CropScience (which was later acquired by Bayer AG). He then worked as an industry consultant, and served on several boards, including Bayer CropScience AG, Gerresheimer AG, Allessa GmbH and Direvo Industrial Biotechnology GmbH. He studied Agriculture at Kiel University in Germany, and finished his Ph.D. in Agricultural Sciences in 1970. Dr. Prante has served on numerous industry associations, at times as their president, including German Crop Protection and Fertilizer Association (IVA), Europe Crop Protection Association (ECPA), Global Crop Protection Federation (GCPF), Global Plant Science Industry Federation (Croplife International), German Association of Biotech Industry (DIB), and the Federation of Sustainable Agriculture. In his career, Dr. Prante has been a strong proponent of the integration of biotechnology into agribusiness since the mid-1980s, led the $0.7 billion acquisition of Plant Genetic Systems by AgrEvo, and built the InVigor canola business in Canada, in addition to buying and integrating several seed companies.
Mark Finn

自2009年以来,Mark Finn一直担任Cibus Ltd.的董事会成员,并一直担任Cibus Global的董事会成员,Finn先生在该公司担任财务和审计委员会主席。Finn先生自1986年起担任Vantage Consulting Group的董事长兼首席执行官。芬恩先生以前参与的机构包括Virginia National银行、弗吉尼亚州退休计划投资咨询委员会和弗吉尼亚州退休制度信托委员会。Finn先生还担任阿拉斯加州退休系统的运营咨询委员会主席。Finn先生也是RF&P Corporation(一家私人持有的铁路和房地产公司)的前董事会主席。目前,Finn先生担任Auven Therapeutics的顾问委员会成员,这是一家专注于生命科学投资的私人股本公司,也是New Ventures I、II和III的管理成员,这三家公司都是专注于梦百合的风险基金。他也是Enterin Inc.Private(生命科学公司,专注于帕金森氏病)的董事。1989年以来,他担任Legg Mason赞助的几个开放式基金的独立受托人。他曾任教于the University of Virginia Graduate Business School,以及the College of William and Mary&8217;s Mason School of Business,在那里他于1987年获得工商管理硕士学位。


Mark Finn serves on the Board of Directors of Cibus Ltd. and has served on the Board of Directors of Cibus Global, where Mr. Finn has chaired the Finance and Audit Committee, since 2009. Mr. Finn has been the Chairman and Chief Executive Officer of the Vantage Consulting Group since 1986. Mr. Finn’s previous involvements include the Virginia National Bank, the State of Virginia Retirement Plan’s Investment Advisory Committee, and the Board of Trustees of the Virginia Retirement System. Mr. Finn also chaired the Operations Advisory Committee for the State of Alaska Retirement System. Mr. Finn is also former Chairman of the Board of Directors of RF&P Corporation, a privately held railroad and real estate company. Currently Mr. Finn serves on the advisory board of Auven Therapeutics, a private equity company focused on life science investment, as well as Managing Member of New Ventures I, II and III, all venture funds focused on healthcare. He also is a Director of Enterin Inc. private, a life sciences company focused on Parkinson’s disease. Since 1989 he has served as an Independent Trustee of several open-end funds sponsored by Legg Mason. He has taught at the University of Virginia Graduate Business School and the College of William and Mary’s Mason School of Business, where he received his M.B.A. in 1987.
自2009年以来,Mark Finn一直担任Cibus Ltd.的董事会成员,并一直担任Cibus Global的董事会成员,Finn先生在该公司担任财务和审计委员会主席。Finn先生自1986年起担任Vantage Consulting Group的董事长兼首席执行官。芬恩先生以前参与的机构包括Virginia National银行、弗吉尼亚州退休计划投资咨询委员会和弗吉尼亚州退休制度信托委员会。Finn先生还担任阿拉斯加州退休系统的运营咨询委员会主席。Finn先生也是RF&P Corporation(一家私人持有的铁路和房地产公司)的前董事会主席。目前,Finn先生担任Auven Therapeutics的顾问委员会成员,这是一家专注于生命科学投资的私人股本公司,也是New Ventures I、II和III的管理成员,这三家公司都是专注于梦百合的风险基金。他也是Enterin Inc.Private(生命科学公司,专注于帕金森氏病)的董事。1989年以来,他担任Legg Mason赞助的几个开放式基金的独立受托人。他曾任教于the University of Virginia Graduate Business School,以及the College of William and Mary&8217;s Mason School of Business,在那里他于1987年获得工商管理硕士学位。
Mark Finn serves on the Board of Directors of Cibus Ltd. and has served on the Board of Directors of Cibus Global, where Mr. Finn has chaired the Finance and Audit Committee, since 2009. Mr. Finn has been the Chairman and Chief Executive Officer of the Vantage Consulting Group since 1986. Mr. Finn’s previous involvements include the Virginia National Bank, the State of Virginia Retirement Plan’s Investment Advisory Committee, and the Board of Trustees of the Virginia Retirement System. Mr. Finn also chaired the Operations Advisory Committee for the State of Alaska Retirement System. Mr. Finn is also former Chairman of the Board of Directors of RF&P Corporation, a privately held railroad and real estate company. Currently Mr. Finn serves on the advisory board of Auven Therapeutics, a private equity company focused on life science investment, as well as Managing Member of New Ventures I, II and III, all venture funds focused on healthcare. He also is a Director of Enterin Inc. private, a life sciences company focused on Parkinson’s disease. Since 1989 he has served as an Independent Trustee of several open-end funds sponsored by Legg Mason. He has taught at the University of Virginia Graduate Business School and the College of William and Mary’s Mason School of Business, where he received his M.B.A. in 1987.
Keith Walker

Keith Walker担任Cibus Ltd.的董事会成员,并自2014年7月起担任Cibus Global的董事会成员。Walker博士于2014年创立Valley Oils,目前担任其董事会主席。Walker博士从2001年11月到2015年7月担任Cibus Global’;的总裁兼首席执行官,在将Valigen的工厂和工业产品部门转变为Cibus Global并从而创立Cibus Global方面发挥了重要作用。此前,Walker博士在AgriGenetics,Inc.任职,并在其收购AgriGenetics,Inc.后,在Mycogen Seeds(一家农业公司,从事某些作物的遗传学研究,开发和测试)担任各种管理职位。他也是Plant Genetics,Inc.的联合创始人、董事和研究Vice President。创立PGI公司之前,Walker博士曾担任Monsanto公司(一家农业生物技术公司)的多种研究职务。他在伍斯特学院(College of Wooster)获得学士学位,在耶鲁大学(Yale University)获得生物学博士学位。


Keith Walker serves on the Board of Directors of Cibus Ltd. and has served on the Board of Directors of Cibus Global since July 2014. In 2014 Dr. Walker founded Valley Oils and currently serves as Chairman of its Board of Directors. Dr. Walker was instrumental in transforming the Plant and Industrial Products Division of ValiGen into, and thus founding, Cibus Global, and served as Cibus Global’s President and Chief Executive Officer from November 2001 to July 2015. Previously, Dr. Walker worked at Agrigenetics, Inc. and held a variety of management positions at Mycogen Seeds, an agricultural company that engages in the research, development, and testing of genetics in certain crops, after it acquired Agrigenetics, Inc. He was also a co-founder, director, and Vice President of Research at Plant Genetics, Inc. “PGI”. Before founding PGI, Dr. Walker served in a variety of research roles with Monsanto, an agricultural biotechnology company. He received a B.A. from the College of Wooster and a Ph.D. in Biology from Yale University.
Keith Walker担任Cibus Ltd.的董事会成员,并自2014年7月起担任Cibus Global的董事会成员。Walker博士于2014年创立Valley Oils,目前担任其董事会主席。Walker博士从2001年11月到2015年7月担任Cibus Global’;的总裁兼首席执行官,在将Valigen的工厂和工业产品部门转变为Cibus Global并从而创立Cibus Global方面发挥了重要作用。此前,Walker博士在AgriGenetics,Inc.任职,并在其收购AgriGenetics,Inc.后,在Mycogen Seeds(一家农业公司,从事某些作物的遗传学研究,开发和测试)担任各种管理职位。他也是Plant Genetics,Inc.的联合创始人、董事和研究Vice President。创立PGI公司之前,Walker博士曾担任Monsanto公司(一家农业生物技术公司)的多种研究职务。他在伍斯特学院(College of Wooster)获得学士学位,在耶鲁大学(Yale University)获得生物学博士学位。
Keith Walker serves on the Board of Directors of Cibus Ltd. and has served on the Board of Directors of Cibus Global since July 2014. In 2014 Dr. Walker founded Valley Oils and currently serves as Chairman of its Board of Directors. Dr. Walker was instrumental in transforming the Plant and Industrial Products Division of ValiGen into, and thus founding, Cibus Global, and served as Cibus Global’s President and Chief Executive Officer from November 2001 to July 2015. Previously, Dr. Walker worked at Agrigenetics, Inc. and held a variety of management positions at Mycogen Seeds, an agricultural company that engages in the research, development, and testing of genetics in certain crops, after it acquired Agrigenetics, Inc. He was also a co-founder, director, and Vice President of Research at Plant Genetics, Inc. “PGI”. Before founding PGI, Dr. Walker served in a variety of research roles with Monsanto, an agricultural biotechnology company. He received a B.A. from the College of Wooster and a Ph.D. in Biology from Yale University.
August Moretti

August Moretti自2019年1月起担任我们的首席财务官。Moretti先生曾于2012年1月至2018年8月担任Assertio Therapeutics(前身为Depomed,Inc.)的首席财务官,该公司是一家专注于疼痛和神经病学的上市专业制药公司。从2004年到2011年12月,莫雷蒂先生担任AlexzaPharmaceuticals,Inc.公司(一家上市制药公司)的首席财务官兼高级副总裁。从2001年到2004年,莫雷蒂先生担任阿拉维塔公司(Alavita,Inc.)的首席财务官and General Counsel,这是一家私人控股的个性化医疗公司。从1982年到2000年,Moretti先生是一家国际律师事务所的合伙人。Moretti先生于1972年在普林斯顿大学(Princeton University)获得经济学学士学位。他于1975年获得Harvard Law School的法学博士学位。


August Moretti has served as our Chief Financial Officer since January 2019. Mr. Moretti previously served as Chief Financial Officer at Assertio Therapeutics formerly Depomed, Inc., a publicly held specialty pharmaceuticals company focused in pain and neurology, from January 2012 until August 2018. From 2004 to December 2011 Mr. Moretti served as Chief Financial Officer and Senior Vice President of Alexza Pharmaceuticals, Inc., a publicly-held pharmaceutical company. From 2001 to 2004 Mr. Moretti served as Chief Financial Officer and General Counsel of Alavita, Inc., a privately held personalized medicine company. From 1982 to 2000 Mr. Moretti was a partner in an international law firm. Mr. Moretti received his B.A. in Economics from Princeton University in 1972. He received his J.D. from Harvard Law School in 1975.
August Moretti自2019年1月起担任我们的首席财务官。Moretti先生曾于2012年1月至2018年8月担任Assertio Therapeutics(前身为Depomed,Inc.)的首席财务官,该公司是一家专注于疼痛和神经病学的上市专业制药公司。从2004年到2011年12月,莫雷蒂先生担任AlexzaPharmaceuticals,Inc.公司(一家上市制药公司)的首席财务官兼高级副总裁。从2001年到2004年,莫雷蒂先生担任阿拉维塔公司(Alavita,Inc.)的首席财务官and General Counsel,这是一家私人控股的个性化医疗公司。从1982年到2000年,Moretti先生是一家国际律师事务所的合伙人。Moretti先生于1972年在普林斯顿大学(Princeton University)获得经济学学士学位。他于1975年获得Harvard Law School的法学博士学位。
August Moretti has served as our Chief Financial Officer since January 2019. Mr. Moretti previously served as Chief Financial Officer at Assertio Therapeutics formerly Depomed, Inc., a publicly held specialty pharmaceuticals company focused in pain and neurology, from January 2012 until August 2018. From 2004 to December 2011 Mr. Moretti served as Chief Financial Officer and Senior Vice President of Alexza Pharmaceuticals, Inc., a publicly-held pharmaceutical company. From 2001 to 2004 Mr. Moretti served as Chief Financial Officer and General Counsel of Alavita, Inc., a privately held personalized medicine company. From 1982 to 2000 Mr. Moretti was a partner in an international law firm. Mr. Moretti received his B.A. in Economics from Princeton University in 1972. He received his J.D. from Harvard Law School in 1975.
Jean Pierre Lehmann

Jean Pierre Lehmann,自2009年11月起担任Cibus全球董事会成员。他被任命为与合并交易有关的Cibus董事会成员。过去30年,莱曼先生一直是一名私人投资者,在风险投资、私募股权方面拥有多元化的投资组合,尤其是在亚洲,以及美国的酒店、商业和住宅房地产。在此之前,Lehmann先生居住在瑞士日内瓦,在那里他为Morval Bank及其控股公司管理投资组合。此前,他曾为Edmond de Rothschild监管一家多元化的控股公司。Lehmann先生毕业于巴黎高等商业学院,拥有哈佛商学院工商管理硕士学位。他也是法国海军的一名军官。


Jean Pierre Lehmann,served on the Cibus Global Board since November 2009. He was appointed to the Board of Cibus in connection with the Merger Transactions. Mr. Lehmann has been a private investor for the past 30 years, with a diversified portfolio in venture capital, private equity, especially in Asia, as well as hotels and commercial and residential real estate in the United States. Prior to this, Mr. Lehmann resided in Geneva, Switzerland, where he managed portfolios for Morval Bank and its holding company. He previously oversaw a diversified holding company for Edmond de Rothschild. Mr. Lehmann is a graduate of the Ecole des Hautes Etudes Commerciales in Paris and holds an M.B.A. from Harvard Business School. He was also an officer in the French Navy.
Jean Pierre Lehmann,自2009年11月起担任Cibus全球董事会成员。他被任命为与合并交易有关的Cibus董事会成员。过去30年,莱曼先生一直是一名私人投资者,在风险投资、私募股权方面拥有多元化的投资组合,尤其是在亚洲,以及美国的酒店、商业和住宅房地产。在此之前,Lehmann先生居住在瑞士日内瓦,在那里他为Morval Bank及其控股公司管理投资组合。此前,他曾为Edmond de Rothschild监管一家多元化的控股公司。Lehmann先生毕业于巴黎高等商业学院,拥有哈佛商学院工商管理硕士学位。他也是法国海军的一名军官。
Jean Pierre Lehmann,served on the Cibus Global Board since November 2009. He was appointed to the Board of Cibus in connection with the Merger Transactions. Mr. Lehmann has been a private investor for the past 30 years, with a diversified portfolio in venture capital, private equity, especially in Asia, as well as hotels and commercial and residential real estate in the United States. Prior to this, Mr. Lehmann resided in Geneva, Switzerland, where he managed portfolios for Morval Bank and its holding company. He previously oversaw a diversified holding company for Edmond de Rothschild. Mr. Lehmann is a graduate of the Ecole des Hautes Etudes Commerciales in Paris and holds an M.B.A. from Harvard Business School. He was also an officer in the French Navy.
Craig Wichner

Craig Wichner是Farmland LP(“Farmland”)的创始人和管理合伙人,该公司是美国领先的农田投资管理公司,拥有超过3.5亿美元的资产,管理的土地超过1.9万英亩。他在2009年创立了Farmland,以证明有机和再生农田管理可以提高土壤健康和长期投资绩效。在创立Farmland之前,Wichner先生创立并管理了几家专注于数据驱动的商业模式和可持续增长的技术和投资公司。他此前曾在Niman Ranch的继任公司BN Ranch的董事会任职,该公司已被Blue Apron Holdings, Inc.(NYSE:APRN)收购。他还管理私人家族房地产资产。Wichner先生拥有加州大学圣地亚哥分校生物化学和分子生物学理学学士学位,辅修经济学。


Craig Wichner,is the Founder and Managing Partner of Farmland LP ("Farmland"), a leading U.S. farmland investment management firm with more than $350 million in assets and over 19,000 acres under management. He founded Farmland in 2009 to demonstrate that organic and regenerative farmland management can enhance both soil health and long-term investment performance. Prior to founding Farmland, Mr. Wichner founded and managed several technology and investment companies focused on data-driven business models and sustainable growth. He previously served on the Board of Directors of BN Ranch, the successor company to Niman Ranch, which was acquired by Blue Apron Holdings, Inc. (NYSE: APRN). He also manages private family real estate holdings. Mr. Wichner holds a Bachelor of Science degree in Biochemistry and Molecular Biology with a minor in Economics from the University of California, San Diego.
Craig Wichner是Farmland LP(“Farmland”)的创始人和管理合伙人,该公司是美国领先的农田投资管理公司,拥有超过3.5亿美元的资产,管理的土地超过1.9万英亩。他在2009年创立了Farmland,以证明有机和再生农田管理可以提高土壤健康和长期投资绩效。在创立Farmland之前,Wichner先生创立并管理了几家专注于数据驱动的商业模式和可持续增长的技术和投资公司。他此前曾在Niman Ranch的继任公司BN Ranch的董事会任职,该公司已被Blue Apron Holdings, Inc.(NYSE:APRN)收购。他还管理私人家族房地产资产。Wichner先生拥有加州大学圣地亚哥分校生物化学和分子生物学理学学士学位,辅修经济学。
Craig Wichner,is the Founder and Managing Partner of Farmland LP ("Farmland"), a leading U.S. farmland investment management firm with more than $350 million in assets and over 19,000 acres under management. He founded Farmland in 2009 to demonstrate that organic and regenerative farmland management can enhance both soil health and long-term investment performance. Prior to founding Farmland, Mr. Wichner founded and managed several technology and investment companies focused on data-driven business models and sustainable growth. He previously served on the Board of Directors of BN Ranch, the successor company to Niman Ranch, which was acquired by Blue Apron Holdings, Inc. (NYSE: APRN). He also manages private family real estate holdings. Mr. Wichner holds a Bachelor of Science degree in Biochemistry and Molecular Biology with a minor in Economics from the University of California, San Diego.
Kimberly A. Box

Kimberly A. Box,2018年当选公司董事,现任薪酬委员会主席。Box女士此前担任Gatekeeper Innovation,Inc.的总裁兼首席执行官,该公司是一家医疗保健公司,致力于创造确保药物安全的产品。她于2016年加入公司。在加入Gatekeeper Innovation之前,Box女士在惠普企业(NYSE:HPQ)拥有成功的29年职业生涯,担任过多个高管职位,最近的一次是全球IT服务副总裁,该职位她一直担任到2009年离开惠普企业。Box女士还担任Applied Science,Inc.(“ASI”)和前American River Bank(NASDAQ:AMRB)的董事会成员,直到该公司于2021年被收购。Box女士拥有加州州立大学奇科分校管理学专业的工商管理理学学士学位和计算机科学专业的辅修学位。她还在宾夕法尼亚大学沃顿商学院完成了高管发展课程,并获得了NACD Directorship Certification(2021年)和卡内基梅隆大学软件工程学院网络安全监督专业的CERT(2022年)。Box女士是NACD北加州分会董事会成员,最近担任主席,并入选NACD Directorship 100,这是对对董事会实践和业绩产生重大影响的领先企业董事的年度表彰。


Kimberly A. Box,was elected a director of the Company in 2018 and currently serves as Chair, Compensation Committee. Ms. Box was previously the President and Chief Executive Officer of Gatekeeper Innovation, Inc., a healthcare company that creates products to keep medications safe. She joined the company in 2016. Prior to joining Gatekeeper Innovation, Ms. Box enjoyed a successful 29-year career with Hewlett Packard (NYSE: HPQ), holding various executive positions, the most recent being Vice President Global IT Services, a position she held until 2009 when she left Hewlett Packard. Ms. Box also serves on the Board of Directors of Applied Science, Inc. ("ASI") and formerly American River Bank (NASDAQ: AMRB) until it was acquired in 2021. Ms. Box holds a Bachelor of Science in Business Administration with a concentration in Management and a minor in Computer Science from California State University, Chico. She also completed the Executive Development Program at The Wharton School of the University of Pennsylvania and has a NACD Directorship Certification(2021) and a CERT in Cybersecurity Oversight from the Software Engineering Institute at Carnegie Mellon University (2022). Ms. Box is on the NACD Northern California Chapter board and recently served as the Chair, and was named to the NACD Directorship 100, an annual recognition of the leading corporate directors who significantly impact boardroom practices and performance.
Kimberly A. Box,2018年当选公司董事,现任薪酬委员会主席。Box女士此前担任Gatekeeper Innovation,Inc.的总裁兼首席执行官,该公司是一家医疗保健公司,致力于创造确保药物安全的产品。她于2016年加入公司。在加入Gatekeeper Innovation之前,Box女士在惠普企业(NYSE:HPQ)拥有成功的29年职业生涯,担任过多个高管职位,最近的一次是全球IT服务副总裁,该职位她一直担任到2009年离开惠普企业。Box女士还担任Applied Science,Inc.(“ASI”)和前American River Bank(NASDAQ:AMRB)的董事会成员,直到该公司于2021年被收购。Box女士拥有加州州立大学奇科分校管理学专业的工商管理理学学士学位和计算机科学专业的辅修学位。她还在宾夕法尼亚大学沃顿商学院完成了高管发展课程,并获得了NACD Directorship Certification(2021年)和卡内基梅隆大学软件工程学院网络安全监督专业的CERT(2022年)。Box女士是NACD北加州分会董事会成员,最近担任主席,并入选NACD Directorship 100,这是对对董事会实践和业绩产生重大影响的领先企业董事的年度表彰。
Kimberly A. Box,was elected a director of the Company in 2018 and currently serves as Chair, Compensation Committee. Ms. Box was previously the President and Chief Executive Officer of Gatekeeper Innovation, Inc., a healthcare company that creates products to keep medications safe. She joined the company in 2016. Prior to joining Gatekeeper Innovation, Ms. Box enjoyed a successful 29-year career with Hewlett Packard (NYSE: HPQ), holding various executive positions, the most recent being Vice President Global IT Services, a position she held until 2009 when she left Hewlett Packard. Ms. Box also serves on the Board of Directors of Applied Science, Inc. ("ASI") and formerly American River Bank (NASDAQ: AMRB) until it was acquired in 2021. Ms. Box holds a Bachelor of Science in Business Administration with a concentration in Management and a minor in Computer Science from California State University, Chico. She also completed the Executive Development Program at The Wharton School of the University of Pennsylvania and has a NACD Directorship Certification(2021) and a CERT in Cybersecurity Oversight from the Software Engineering Institute at Carnegie Mellon University (2022). Ms. Box is on the NACD Northern California Chapter board and recently served as the Chair, and was named to the NACD Directorship 100, an annual recognition of the leading corporate directors who significantly impact boardroom practices and performance.

高管简历

中英对照 |  中文 |  英文
Peter Beetham

Peter Beetham是Cibus Global的联合创始人,担任Cibus Ltd.的首席执行官兼总裁,并自2014年7月起担任Cibus Global的首席执行官兼总裁。Beetham先生还任职于Cibus Ltd.的董事会。此前,Beetham博士是Cibus Global研究与开发的高级副总裁,并担任其他行政职务。Beetham博士拥有超过30年的农业经验。加入Cibus公司之前,他曾担任Valigen公司的工厂和工业产品部门的研究董事,以及Kimeragen公司的高级科学家,在那里他曾领导研究团队探索基因靶向。他丰富的研究经验的一部分是在康奈尔大学(Cornell University)的博伊斯·汤普森研究所(Boyce Thompson Institute),在那里他是博士后科学家和导致Cibus RTDS技术的早期工作的先驱之一。Beetham博士从1985年到1992年受雇于澳大利亚维多利亚州农业和农村事务部。他曾担任植物研究所(the Plant Research Institute)的科学官员,与东南亚和南太平洋的研究团体合作。Beetham博士在澳大利亚布里斯班QUT获得植物分子病毒学博士学位,是理学学士学位。莫纳什大学荣誉毕业生,墨尔本,澳大利亚。


Peter Beetham is a co-founder of Cibus Global and serves as Cibus Ltd.’s Chief Executive Officer & President and has served as the Chief Executive Officer & President of Cibus Global since July 2014. Mr. Beetham also serves on the Board of Directors of Cibus Ltd. Previously, Dr. Beetham was Senior Vice President of Research and Development at Cibus Global and served in other executive capacities. Dr. Beetham has over 30 years of experience in agriculture. Prior to joining Cibus, Dr. Beetham was Research Director of the Plant and Industrial Products Division at ValiGen and a Senior Scientist at Kimeragen where he led research teams exploring gene targeting. Part of his extensive research experience was at the Boyce Thompson Institute at Cornell University, where he was a postdoctoral scientist and one of the pioneers of the early work that led to the Cibus RTDS technologies. Dr. Beetham was employed by the Department of Agriculture and Rural Affairs, Victoria, Australia from 1985 to 1992. He served as a scientific officer based at the Plant Research Institute, working with research groups throughout Southeast Asia and the South Pacific. Dr. Beetham received his Ph.D. in Plant Molecular Virology from QUT in Brisbane, Australia and is a B.Sc. Hons graduate of Monash University, Melbourne, Australia.
Peter Beetham是Cibus Global的联合创始人,担任Cibus Ltd.的首席执行官兼总裁,并自2014年7月起担任Cibus Global的首席执行官兼总裁。Beetham先生还任职于Cibus Ltd.的董事会。此前,Beetham博士是Cibus Global研究与开发的高级副总裁,并担任其他行政职务。Beetham博士拥有超过30年的农业经验。加入Cibus公司之前,他曾担任Valigen公司的工厂和工业产品部门的研究董事,以及Kimeragen公司的高级科学家,在那里他曾领导研究团队探索基因靶向。他丰富的研究经验的一部分是在康奈尔大学(Cornell University)的博伊斯·汤普森研究所(Boyce Thompson Institute),在那里他是博士后科学家和导致Cibus RTDS技术的早期工作的先驱之一。Beetham博士从1985年到1992年受雇于澳大利亚维多利亚州农业和农村事务部。他曾担任植物研究所(the Plant Research Institute)的科学官员,与东南亚和南太平洋的研究团体合作。Beetham博士在澳大利亚布里斯班QUT获得植物分子病毒学博士学位,是理学学士学位。莫纳什大学荣誉毕业生,墨尔本,澳大利亚。
Peter Beetham is a co-founder of Cibus Global and serves as Cibus Ltd.’s Chief Executive Officer & President and has served as the Chief Executive Officer & President of Cibus Global since July 2014. Mr. Beetham also serves on the Board of Directors of Cibus Ltd. Previously, Dr. Beetham was Senior Vice President of Research and Development at Cibus Global and served in other executive capacities. Dr. Beetham has over 30 years of experience in agriculture. Prior to joining Cibus, Dr. Beetham was Research Director of the Plant and Industrial Products Division at ValiGen and a Senior Scientist at Kimeragen where he led research teams exploring gene targeting. Part of his extensive research experience was at the Boyce Thompson Institute at Cornell University, where he was a postdoctoral scientist and one of the pioneers of the early work that led to the Cibus RTDS technologies. Dr. Beetham was employed by the Department of Agriculture and Rural Affairs, Victoria, Australia from 1985 to 1992. He served as a scientific officer based at the Plant Research Institute, working with research groups throughout Southeast Asia and the South Pacific. Dr. Beetham received his Ph.D. in Plant Molecular Virology from QUT in Brisbane, Australia and is a B.Sc. Hons graduate of Monash University, Melbourne, Australia.
Greg Gocal

Greg Gocal是Cibus Global的联合创始人,担任Cibus Ltd.的首席科学官兼执行Vice President,并于2016年晋升为Cibus Global的首位首席科学官兼执行Vice President。在此之前,他曾于2014年至2016年担任研究与开发Cibus&8217;高级副总裁,并于2010年至2014年担任研究Vice President。2000年,Gocal博士加入Valigen,Cibus&8217;前身的创新跨学科团队,担任首席分子生物学家。在植物和工业产品部门,他的团队开始在植物和微生物系统中开发RTDS套件技术,该领域当时是一个新兴领域,现已成为基因编辑。继续这一重点并使我们的技术和产品管道,在Cibus,Gocal博士担任过各种研究管理职位。Gocal博士研究了植物生物学的许多方面。他在卡尔加里大学(University of Calgary)获得本科和研究生学位。他曾任职澳大利亚堪培拉CSIRO Plant Industry,在那里他获得澳大利亚国立大学(the Australian National University)的植物分子生物学博士学位,随后继续在该领域学习,担任加州拉霍亚的索尔克生物研究所(the Salk Institute for Biological Studies)的博士后科学家。


Greg Gocal is a co-founder of Cibus Global and serves as Cibus Ltd.’s Chief Scientific Officer & Executive Vice President and was promoted to become Cibus Global’s initial Chief Scientific Officer & Executive Vice President in 2016. Prior to that, he served as Cibus’ Senior Vice President of Research and Development from 2014 to 2016 and from 2010 to 2014 served as Vice President of Research. In 2000 Dr. Gocal joined an innovative cross disciplinary team at ValiGen, Cibus’ predecessor, as the lead molecular biologist. Within the Plant and Industrial Products Division, his team began developing the RTDS suite of technologies in plant and microbial systems in what was then the nascent field that has become gene editing. Continuing this focus and enabling our technologies and product pipeline, at Cibus, Dr. Gocal has held various research management positions. Dr. Gocal has studied many aspects of plant biology. He was awarded undergraduate and graduate degrees from the University of Calgary. He worked at CSIRO Plant Industry in Canberra, Australia where he received his Ph.D. in Plant Molecular Biology from the Australian National University, then continued studying in this field as a postdoctoral scientist at the Salk Institute for Biological Studies in La Jolla, California.
Greg Gocal是Cibus Global的联合创始人,担任Cibus Ltd.的首席科学官兼执行Vice President,并于2016年晋升为Cibus Global的首位首席科学官兼执行Vice President。在此之前,他曾于2014年至2016年担任研究与开发Cibus&8217;高级副总裁,并于2010年至2014年担任研究Vice President。2000年,Gocal博士加入Valigen,Cibus&8217;前身的创新跨学科团队,担任首席分子生物学家。在植物和工业产品部门,他的团队开始在植物和微生物系统中开发RTDS套件技术,该领域当时是一个新兴领域,现已成为基因编辑。继续这一重点并使我们的技术和产品管道,在Cibus,Gocal博士担任过各种研究管理职位。Gocal博士研究了植物生物学的许多方面。他在卡尔加里大学(University of Calgary)获得本科和研究生学位。他曾任职澳大利亚堪培拉CSIRO Plant Industry,在那里他获得澳大利亚国立大学(the Australian National University)的植物分子生物学博士学位,随后继续在该领域学习,担任加州拉霍亚的索尔克生物研究所(the Salk Institute for Biological Studies)的博士后科学家。
Greg Gocal is a co-founder of Cibus Global and serves as Cibus Ltd.’s Chief Scientific Officer & Executive Vice President and was promoted to become Cibus Global’s initial Chief Scientific Officer & Executive Vice President in 2016. Prior to that, he served as Cibus’ Senior Vice President of Research and Development from 2014 to 2016 and from 2010 to 2014 served as Vice President of Research. In 2000 Dr. Gocal joined an innovative cross disciplinary team at ValiGen, Cibus’ predecessor, as the lead molecular biologist. Within the Plant and Industrial Products Division, his team began developing the RTDS suite of technologies in plant and microbial systems in what was then the nascent field that has become gene editing. Continuing this focus and enabling our technologies and product pipeline, at Cibus, Dr. Gocal has held various research management positions. Dr. Gocal has studied many aspects of plant biology. He was awarded undergraduate and graduate degrees from the University of Calgary. He worked at CSIRO Plant Industry in Canberra, Australia where he received his Ph.D. in Plant Molecular Biology from the Australian National University, then continued studying in this field as a postdoctoral scientist at the Salk Institute for Biological Studies in La Jolla, California.
Cornelis Broos

Cornelis Bros,担任Cibus的临时首席财务官。此前,Bros先生自2024年起担任公司财务高级副总裁,拥有丰富的公共财务、会计和审计经验。在担任现职之前,Bros先生于2011年加入公司后担任公司财务和业务发展副总裁。在加入公司之前,Bros先生曾于2008年至2011年担任先正达欧洲非洲中东的财务(服务)主管,于2005年至2008年担任先正达的荷兰首席财务官和比利时首席财务官,于2002年至2005年担任Advanta的集团财务总监,并于1995年至2002年担任德勤(荷兰)的审计经理。Bros先生于1995年完成了Radboud大学的工商管理理学硕士学位,并于1999年完成了荷兰蒂尔堡大学的会计学硕士后课程,成为荷兰的注册会计师(相当于注册会计师)。


Cornelis Broos,serves as Cibus' Interim Chief Financial Officer. Previously, Mr. Broos served as Senior Vice President of Finance of the Company since 2024 and has significant public finance, accounting and audit experience. Prior to his current role, Mr. Broos served as the Company's Vice President of Finance and Business Development after joining the Company in 2011. Before joining the Company, Mr. Broos served as the Head of Finance (Services) for Syngenta Europe Africa Middle East from 2008 to 2011, as CFO Netherlands and CFO Belgium for Syngenta from 2005 to 2008, as Group Controller for Advanta from 2002 to 2005 and as Audit Manager at Deloitte (Netherlands) from 1995 to 2002. Mr. Broos completed a Master of Science in Business Administration from Radboud University in 1995 and completed a post-master program in accountancy at Tilburg University in the Netherlands in 1999, becoming Registered Accountant (the equivalent of a CPA) in the Netherlands.
Cornelis Bros,担任Cibus的临时首席财务官。此前,Bros先生自2024年起担任公司财务高级副总裁,拥有丰富的公共财务、会计和审计经验。在担任现职之前,Bros先生于2011年加入公司后担任公司财务和业务发展副总裁。在加入公司之前,Bros先生曾于2008年至2011年担任先正达欧洲非洲中东的财务(服务)主管,于2005年至2008年担任先正达的荷兰首席财务官和比利时首席财务官,于2002年至2005年担任Advanta的集团财务总监,并于1995年至2002年担任德勤(荷兰)的审计经理。Bros先生于1995年完成了Radboud大学的工商管理理学硕士学位,并于1999年完成了荷兰蒂尔堡大学的会计学硕士后课程,成为荷兰的注册会计师(相当于注册会计师)。
Cornelis Broos,serves as Cibus' Interim Chief Financial Officer. Previously, Mr. Broos served as Senior Vice President of Finance of the Company since 2024 and has significant public finance, accounting and audit experience. Prior to his current role, Mr. Broos served as the Company's Vice President of Finance and Business Development after joining the Company in 2011. Before joining the Company, Mr. Broos served as the Head of Finance (Services) for Syngenta Europe Africa Middle East from 2008 to 2011, as CFO Netherlands and CFO Belgium for Syngenta from 2005 to 2008, as Group Controller for Advanta from 2002 to 2005 and as Audit Manager at Deloitte (Netherlands) from 1995 to 2002. Mr. Broos completed a Master of Science in Business Administration from Radboud University in 1995 and completed a post-master program in accountancy at Tilburg University in the Netherlands in 1999, becoming Registered Accountant (the equivalent of a CPA) in the Netherlands.
Noel Sauer

Noel Sauer,自2021年起担任Cibus的研究高级副总裁。在此之前,她曾于2017年至2021年担任Cibus的研究副总裁,并于2017年至2010年担任研究领导,担任多个进步角色,主要专注于启用、推进和扩展Cibus的核心RTDS技术套件。在Cibus,她通过在精准植物育种领域的进步,对技术开发部门进行了核化,并带领团队在商业相关作物中开发非转基因性状。在加入Cibus之前,2010年,在加利福尼亚州圣地亚哥的依诺米那,绍尔博士帮助比尔和梅琳达·盖茨基金会开发技术,以检测第三世界国家临床样本中的地方病原体。从2007年到2009年,Sauer博士帮助领导了位于马萨诸塞州剑桥的Cequent Pharmaceuticals的平台开发工作,使他们的新型治疗技术TKRNAi能够治疗许多人类疾病,如炎症性肠病和预防结肠癌。绍尔博士在南加州大学获得生物科学学士学位,并在哈佛大学获得微生物学和分子遗传学博士学位。为了她的博士后,绍尔博士加入了哈佛医学院麻省总医院,研究宿主-病原体的相互作用。


Noel Sauer,has served as Cibus' Senior Vice President of Research since 2021. Prior to that, she served as Cibus' Vice President of Research from 2017 to 2021, and from 2017 to 2010 as research leadership in several progressive roles primarily focused on enabling, advancing, and expanding Cibus' core RTDS suite of technologies. At Cibus, she has nucleated the technology development department and led teams toward the development of non-transgenic traits in commercially relevant crops through advancements in the field of precision plant breeding. Prior to joining Cibus, in 2010 at Illumina in San Diego, California, Dr. Sauer helped develop technologies for the Bill and Melinda Gates Foundation to detect endemic pathogens in clinical samples in third world countries. From 2007 to 2009, Dr. Sauer helped lead the platform development efforts at Cequent Pharmaceuticals in Cambridge, Massachusetts, enabling their novel therapeutic technology, tkRNAi, to treat many human diseases such as inflammatory bowel disease and in colon-cancer prevention. Dr. Sauer earned her B.S. degree in Biological Sciences from the University of Southern California, and a doctoral degree in Microbiology and Molecular Genetics from Harvard University. For her postdoc, Dr. Sauer joined Massachusetts General Hospital, Harvard Medical School, studying host-pathogen interactions.
Noel Sauer,自2021年起担任Cibus的研究高级副总裁。在此之前,她曾于2017年至2021年担任Cibus的研究副总裁,并于2017年至2010年担任研究领导,担任多个进步角色,主要专注于启用、推进和扩展Cibus的核心RTDS技术套件。在Cibus,她通过在精准植物育种领域的进步,对技术开发部门进行了核化,并带领团队在商业相关作物中开发非转基因性状。在加入Cibus之前,2010年,在加利福尼亚州圣地亚哥的依诺米那,绍尔博士帮助比尔和梅琳达·盖茨基金会开发技术,以检测第三世界国家临床样本中的地方病原体。从2007年到2009年,Sauer博士帮助领导了位于马萨诸塞州剑桥的Cequent Pharmaceuticals的平台开发工作,使他们的新型治疗技术TKRNAi能够治疗许多人类疾病,如炎症性肠病和预防结肠癌。绍尔博士在南加州大学获得生物科学学士学位,并在哈佛大学获得微生物学和分子遗传学博士学位。为了她的博士后,绍尔博士加入了哈佛医学院麻省总医院,研究宿主-病原体的相互作用。
Noel Sauer,has served as Cibus' Senior Vice President of Research since 2021. Prior to that, she served as Cibus' Vice President of Research from 2017 to 2021, and from 2017 to 2010 as research leadership in several progressive roles primarily focused on enabling, advancing, and expanding Cibus' core RTDS suite of technologies. At Cibus, she has nucleated the technology development department and led teams toward the development of non-transgenic traits in commercially relevant crops through advancements in the field of precision plant breeding. Prior to joining Cibus, in 2010 at Illumina in San Diego, California, Dr. Sauer helped develop technologies for the Bill and Melinda Gates Foundation to detect endemic pathogens in clinical samples in third world countries. From 2007 to 2009, Dr. Sauer helped lead the platform development efforts at Cequent Pharmaceuticals in Cambridge, Massachusetts, enabling their novel therapeutic technology, tkRNAi, to treat many human diseases such as inflammatory bowel disease and in colon-cancer prevention. Dr. Sauer earned her B.S. degree in Biological Sciences from the University of Southern California, and a doctoral degree in Microbiology and Molecular Genetics from Harvard University. For her postdoc, Dr. Sauer joined Massachusetts General Hospital, Harvard Medical School, studying host-pathogen interactions.
Jason Stokes

Jason Stokes,担任Cibus的首席法务官、总法律顾问和公司秘书。在此之前,Stokes先生曾于2022年至2023年担任加密货币数据挖掘中心运营商Compute North的首席法务官、总法律顾问和公司秘书(他带领Compute North通过了第11章的破产程序),于2021年至2022年担任半导体制造公司SkyWater Technology(纳斯达克:SKYT)的首席法务官、总法律顾问和秘书,并在水务解决方案和管理公司滨特尔 PLC(NYSE:PNR)担任多个进步职务,包括2015年至2018年公司法律与合规副总裁、协理总法律顾问,2012年至2015年为公司,并作为协理总法律顾问,2011年至2012年为并购。斯托克斯先生还在2018年至2021年期间作为几家公司的签约外部总法律顾问自营职业。此外,斯托克斯先生曾于2007年至2011年担任Hearth & Home Technologies的总法律顾问,2004年至2007年担任Scoular公司的律师,1999年至2004年担任Lindquist & Venum PLLP律师事务所的协理。在从事法律职业之前,斯托克斯先生是美国海军的一名军官,在1993年至1999年期间服役。斯托克斯先生在上市公司和私营公司拥有重要的公司法和证券法、治理、并购、商法以及一般法律和领导经验。斯托克斯先生在乔治敦大学法律中心获得法学博士学位,在圣母大学获得机械工程理学学士学位。


Jason Stokes,serves as Cibus' Chief Legal Officer, General Counsel and Corporate Secretary. Previously, Mr. Stokes served as Chief Legal Officer, General Counsel and Corporate Secretary of Compute North, an operator of cryptocurrency data mining centers, from 2022 to 2023 (where he shepherded Compute North through their Chapter 11 bankruptcy proceedings), as Chief Legal Officer, General Counsel and Secretary of SkyWater Technology (Nasdaq: SKYT), a semi-conductor manufacturing company, from 2021 to 2022, and in several progressive roles at Pentair plc (NYSE: PNR), a water solutions and management company, including Vice President, Corporate Law & Compliance from 2015 to 2018, Associate General Counsel, Corporate from 2012 to 2015 and as Associate General Counsel, M&A from 2011 to 2012. Mr.Stokes was also self-employed as a contracted outside general counsel for several companies from 2018 to 2021. Furthermore, Mr. Stokes served as General Counsel, Hearth & Home Technologies from 2007 to 2011, as an Attorney at The Scoular Company from 2004 to 2007 and as an Associate at the law firm Lindquist & Vennum PLLP from 1999 to 2004. Prior to his legal career, Mr. Stokes was an officer in the United States Navy, serving on active duty from 1993 to 1999. Mr. Stokes has significant corporate and securities law, governance, M&A, commercial law and general legal and leadership experience, in both public and private companies. Mr. Stokes received his Juris Doctor from Georgetown University Law Center and his Bachelor of Science in Mechanical Engineering from the University of Notre Dame.
Jason Stokes,担任Cibus的首席法务官、总法律顾问和公司秘书。在此之前,Stokes先生曾于2022年至2023年担任加密货币数据挖掘中心运营商Compute North的首席法务官、总法律顾问和公司秘书(他带领Compute North通过了第11章的破产程序),于2021年至2022年担任半导体制造公司SkyWater Technology(纳斯达克:SKYT)的首席法务官、总法律顾问和秘书,并在水务解决方案和管理公司滨特尔 PLC(NYSE:PNR)担任多个进步职务,包括2015年至2018年公司法律与合规副总裁、协理总法律顾问,2012年至2015年为公司,并作为协理总法律顾问,2011年至2012年为并购。斯托克斯先生还在2018年至2021年期间作为几家公司的签约外部总法律顾问自营职业。此外,斯托克斯先生曾于2007年至2011年担任Hearth & Home Technologies的总法律顾问,2004年至2007年担任Scoular公司的律师,1999年至2004年担任Lindquist & Venum PLLP律师事务所的协理。在从事法律职业之前,斯托克斯先生是美国海军的一名军官,在1993年至1999年期间服役。斯托克斯先生在上市公司和私营公司拥有重要的公司法和证券法、治理、并购、商法以及一般法律和领导经验。斯托克斯先生在乔治敦大学法律中心获得法学博士学位,在圣母大学获得机械工程理学学士学位。
Jason Stokes,serves as Cibus' Chief Legal Officer, General Counsel and Corporate Secretary. Previously, Mr. Stokes served as Chief Legal Officer, General Counsel and Corporate Secretary of Compute North, an operator of cryptocurrency data mining centers, from 2022 to 2023 (where he shepherded Compute North through their Chapter 11 bankruptcy proceedings), as Chief Legal Officer, General Counsel and Secretary of SkyWater Technology (Nasdaq: SKYT), a semi-conductor manufacturing company, from 2021 to 2022, and in several progressive roles at Pentair plc (NYSE: PNR), a water solutions and management company, including Vice President, Corporate Law & Compliance from 2015 to 2018, Associate General Counsel, Corporate from 2012 to 2015 and as Associate General Counsel, M&A from 2011 to 2012. Mr.Stokes was also self-employed as a contracted outside general counsel for several companies from 2018 to 2021. Furthermore, Mr. Stokes served as General Counsel, Hearth & Home Technologies from 2007 to 2011, as an Attorney at The Scoular Company from 2004 to 2007 and as an Associate at the law firm Lindquist & Vennum PLLP from 1999 to 2004. Prior to his legal career, Mr. Stokes was an officer in the United States Navy, serving on active duty from 1993 to 1999. Mr. Stokes has significant corporate and securities law, governance, M&A, commercial law and general legal and leadership experience, in both public and private companies. Mr. Stokes received his Juris Doctor from Georgetown University Law Center and his Bachelor of Science in Mechanical Engineering from the University of Notre Dame.